Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Datopotamab deruxtecan plus durvalumab versus datopotamab deruxtecan in PD-L1-negative metastatic triple-negative breast cancer
2024-519913-76-00Phase 2Authorised
- Sponsor
- Queen Mary University of London
- Start
- Dec 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Datopotamab deruxtecan + durvalumab with Datopotamab deruxtecan (2 arms). Primary endpoint: Progression-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
datopotamab deruxtecandurvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-519913-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519913-76-00.